Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07247162 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

Study acronym: LINC CARE
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
RECORDATI GROUP
10 trials monitored
See 2 trials at risk
Hypertension
1,925 trials monitored
See 99 trials at risk
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.
Trial Details
NCT Number NCT07247162
Lead Sponsor RECORDATI GROUP
Conditions
(from sponsor)		 Hypertension, Hypercortisolemia, Cushing Syndrome
Related terms ACTH Syndrome, Ectopic, Cushing Syndrome, Hypertension
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov